National Drug Strategy Household Survey, 2022-2023

The 2022–2023 National Drug Strategy Household Survey was conducted in two phases, the first between July and December of 2022 and the second between March and May 2023. The survey examines current awareness of attitudes and behaviours toward drugs and drug problems within the Australian community, focusing on respondents' personal attitudes toward drugs, knowledge of drugs and drug histories. The survey included questions regarding respondents' personal drug and alcohol experience and behaviour, opinions on drug policy and legislation, availability of drugs and alcohol, injury and harm from drugs and alcohol, and attitudes towards the use of alcohol and other drugs. The drugs covered included: tobacco/cigarettes, e-cigarettes/vapes, alcohol, kava, pain-killers/pain-relievers and opioids, tranquillisers, heroin, methadone, inhalants, ketamine, GHB, ecstasy, hallucinogens, cocaine, methamphetamine and amphetamine, pharmaceutical stimulants, cannabis/marijuana, synthetic cannabis, other psychoactive substances, and steroids. Demographic and background variables included: state of residence, age, gender, marital status, self-assessed health status, sexuality, Indigenous status, country of birth, language spoken at home, employment status, occupation, level of education, income, index of socio-economic advantage and disadvantage, remoteness area and household composition.

2022-2023年度全国药物战略家庭调查分为两个阶段实施，第一阶段于2022年7月至12月进行，第二阶段于2023年3月至5月进行。本次调查旨在探究澳大利亚社区中关于药物及其问题的态度与行为现状，重点关注受访者对药物的个人态度、药物知识与药物使用史。调查内容涵盖受访者个人药物与酒精体验及行为、对药物政策与立法的看法、药物与酒精的获取途径、药物与酒精引起的伤害及对酒精及其他药物使用的态度。调查涉及的药物包括：烟草/香烟、电子烟/雾化器、酒精、库瓦（一种植物）、止痛药/止痛剂和阿片类药物、镇静剂、海洛因、美沙酮、吸入剂、K他命、GHB、摇头丸、致幻剂、可卡因、甲基苯丙胺和苯丙胺、药理性兴奋剂、大麻/大麻花、合成大麻、其他致幻物质和类固醇。调查还包括人口统计学和背景变量，如居住地、年龄、性别、婚姻状况、自我评估的健康状况、性取向、原住民身份、出生国、家庭语言、就业状况、职业、教育水平、收入、社会经济优势与劣势指数、偏远地区和家庭成员构成。